US Patent

US12528787 — Solid state forms of a kinase inhibitor

Composition of Matter · Assigned to Deciphera Pharmaceuticals LLC · Expires 2044-12-06 · 19y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects solid-state forms of a compound, pharmaceutical compositions containing these forms, and methods for making and using them.

USPTO Abstract

Described herein, in part, are solid-state forms of the compound represented by Formula (I), pharmaceutical compositions comprising the solid-state forms, processes of making the solid-state forms and methods of using the solid-state forms

Drugs covered by this patent

Patent Metadata

Patent number
US12528787
Jurisdiction
US
Classification
Composition of Matter
Expires
2044-12-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Deciphera Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.